Close Menu

NEW YORK – With the recent launch of Target-NG, an assay to determine antimicrobial susceptibility of gonorrhea infections, San Jose, California-based startup Shield Bio appears to be the first commercial clinical laboratory in the US to offer a nanopore sequencing-based assay for routine diagnostic testing.

Shield is also developing its technology for other applications — including hospital-acquired infection and sepsis testing — relying on the advantages that sequencing has for detecting a large number of evolving resistance mechanisms as compared to PCR-based tests.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.